GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (STU:49B) » Definitions » Cyclically Adjusted PS Ratio

BeOne Medicines (STU:49B) Cyclically Adjusted PS Ratio : 18.87 (As of Jun. 01, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines Cyclically Adjusted PS Ratio?

As of today (2025-06-01), BeOne Medicines's current share price is €17.17. BeOne Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €0.91. BeOne Medicines's Cyclically Adjusted PS Ratio for today is 18.87.

The historical rank and industry rank for BeOne Medicines's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:49B' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.31   Med: 18.37   Max: 22.73
Current: 18.7

During the past years, BeOne Medicines's highest Cyclically Adjusted PS Ratio was 22.73. The lowest was 14.31. And the median was 18.37.

STU:49B's Cyclically Adjusted PS Ratio is ranked worse than
82.06% of 496 companies
in the Biotechnology industry
Industry Median: 5.345 vs STU:49B: 18.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BeOne Medicines's adjusted revenue per share data for the three months ended in Mar. 2025 was €0.715. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.91 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


BeOne Medicines Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BeOne Medicines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Cyclically Adjusted PS Ratio Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 15.44

BeOne Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.28 14.50 20.73 15.44 20.71

Competitive Comparison of BeOne Medicines's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PS Ratio falls into.


;
;

BeOne Medicines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BeOne Medicines's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=17.17/0.91
=18.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BeOne Medicines's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.715/107.7224*107.7224
=0.715

Current CPI (Mar. 2025) = 107.7224.

BeOne Medicines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.002 100.464 0.002
201509 0.002 99.785 0.002
201512 0.010 99.386 0.011
201603 0.002 99.475 0.002
201606 0.001 100.088 0.001
201609 0.000 99.604 0.000
201612 0.000 99.380 0.000
201703 0.000 100.040 0.000
201706 0.000 100.285 0.000
201709 0.308 100.254 0.331
201712 0.026 100.213 0.028
201803 0.039 100.836 0.042
201806 0.065 101.435 0.069
201809 0.063 101.246 0.067
201812 0.067 100.906 0.072
201903 0.089 101.571 0.094
201906 0.277 102.044 0.292
201909 0.058 101.396 0.062
201912 0.065 101.063 0.069
202003 0.047 101.048 0.050
202006 0.058 100.743 0.062
202009 0.067 100.585 0.072
202012 0.070 100.241 0.075
202103 0.405 100.800 0.433
202106 0.104 101.352 0.111
202109 0.146 101.533 0.155
202112 0.153 101.776 0.162
202203 0.209 103.205 0.218
202206 0.242 104.783 0.249
202209 0.291 104.835 0.299
202212 0.266 104.666 0.274
202303 0.309 106.245 0.313
202306 0.404 106.576 0.408
202309 0.527 106.570 0.533
202312 0.430 106.461 0.435
202403 0.510 107.355 0.512
202406 0.634 107.991 0.632
202409 0.655 107.468 0.657
202412 0.774 107.128 0.778
202503 0.715 107.722 0.715

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BeOne Medicines  (STU:49B) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BeOne Medicines Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines